Entera Bio (ENTX) Cash from Financing Activities (2021 - 2026)
Entera Bio (ENTX) posted quarterly Cash from Financing Activities of $130000.0 for Q1 2026, down 99.03% year-on-year from $13.3 million in Q1 2025, and down 25.29% on a QoQ basis from $174000.0 in Q4 2025.
Entera Bio (ENTX) Cash from Financing Activities (2021 - 2026) Analysis & Trends
Entera Bio (ENTX) has reported Cash from Financing Activities for 6 consecutive years, with $130000.0 the latest figure, recorded in Q1 2026.
- Quarterly Cash from Financing Activities fell 99.03% year-over-year to $130000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $503000.0 (down 97.17% YoY) and the FY2025 annual result came in at $13.7 million, up 206.3% from the prior year.
- Cash from Financing Activities retreated to $130000.0 in Q1 2026 per ENTX's latest filing, from $174000.0 in the prior quarter.
- Over the last five years, Cash from Financing Activities for ENTX reached as high as $13.3 million in Q1 2025 and fell as low as -$51000.0 in Q2 2025.
- A 5-year average of $2.0 million and a median of $152000.0 in 2025 frame the typical range for Cash from Financing Activities.
- The largest YoY upside for Cash from Financing Activities was 44356.67% in 2025 against a maximum downside of 104.19% in 2025.
- Year by year, Cash from Financing Activities stood at $13000.0 in 2022, then jumped by 46292.31% to $6.0 million in 2023, then plunged by 46.66% to $3.2 million in 2024, then slumped by 94.59% to $174000.0 in 2025, then retreated by 25.29% to $130000.0 in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $130000.0, $174000.0, and $250000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 53,000.00 |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 68.63 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 238.74 Mn |
| 10 | Entera Bio | 186.78 Mn | 182.64 Mn | - | 130,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 130,000.00 |
| Mar 31, 2026 | 130,000.00 |
| Dec 31, 2025 | 174,000.00 |
| Dec 31, 2025 | 174,000.00 |
| Sep 30, 2025 | 250,000.00 |
| Sep 30, 2025 | 250,000.00 |
| Jun 30, 2025 | -51,000.00 |
| Jun 30, 2025 | -51,000.00 |
| Mar 31, 2025 | 13.34 Mn |
| Mar 31, 2025 | 13.34 Mn |
| Dec 31, 2024 | 3.22 Mn |
| Dec 31, 2024 | 3.22 Mn |
| Sep 30, 2024 | 13,000.00 |
| Sep 30, 2024 | 13,000.00 |
| Jun 30, 2024 | 1.22 Mn |
| Jun 30, 2024 | 1.22 Mn |
| Mar 31, 2024 | 30,000.00 |
| Mar 31, 2024 | 30,000.00 |
| Dec 31, 2023 | 6.03 Mn |
| Dec 31, 2023 | 6.03 Mn |